Aromasin (exemestane) is now officially approved for POSTmenopausal women with early stage breast cancer
August 2006
Aromasin (exemestane) is now officially approved for POSTmenopausal women with early stage breast cancer, who've received 2 to 3 years of tamoxifen.
Aromasin and tamoxifen work differently. Tamoxifen blocks estrogen receptors...and Aromasin blocks estrogen synthesis.
About 30% of women taking tamoxifen complain of side effects such as hot flashes, vaginal discharge, and vaginal bleeding.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote